HLB (HLB) announced on the 13th that its subsidiary Eleva and its partner, Hangseo Pharmaceutical of China, had applied for a pre-NDA meeting with the US Food and Drug Administration (FDA) for approval for ‘Rivoceranib’ as the first-line treatment for liver cancer. 

Please refer to the following website for further details:   

https://korea.postsen.com/business/53218/HLB-Apply-for-riboceranib-pre-NDA-meeting-with-US-FDA.html